Even though there is conflicting evidence whether ERG could be a biomarker for PCa aggressiveness, several studies indicate that distinct molecular mechanisms are at play in ERG negative vs. ERG positive tumors; thus, ERG in combination with other biomarkers might be a valuable biomarker for PCa aggressiveness [8,9,10]. The gene discussed is ERG; the disease is posterior cortical atrophy.